Insider Selling: AtriCure, Inc. (NASDAQ:ATRC) Insider Sells 1,500 Shares of Stock

AtriCure, Inc. (NASDAQ:ATRCGet Free Report) insider Justin J. Noznesky sold 1,500 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $30.39, for a total value of $45,585.00. Following the sale, the insider now directly owns 72,784 shares of the company’s stock, valued at $2,211,905.76. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

AtriCure Stock Performance

NASDAQ ATRC opened at $27.21 on Wednesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.57 and a quick ratio of 2.66. AtriCure, Inc. has a 12 month low of $26.92 and a 12 month high of $59.61. The stock has a 50 day moving average of $33.02 and a 200-day moving average of $35.79.

AtriCure (NASDAQ:ATRCGet Free Report) last released its quarterly earnings data on Thursday, February 15th. The medical device company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.01. The company had revenue of $106.50 million during the quarter, compared to the consensus estimate of $103.68 million. AtriCure had a negative return on equity of 7.55% and a negative net margin of 7.62%. The firm’s revenue for the quarter was up 21.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.09) EPS. As a group, equities analysts expect that AtriCure, Inc. will post -0.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On AtriCure

Several hedge funds have recently added to or reduced their stakes in ATRC. RiverPark Advisors LLC acquired a new stake in AtriCure during the 3rd quarter valued at $27,000. Virtus Fund Advisers LLC acquired a new stake in AtriCure during the 4th quarter valued at $27,000. Arcadia Investment Management Corp MI acquired a new stake in AtriCure during the 3rd quarter valued at $28,000. KBC Group NV acquired a new stake in AtriCure during the 4th quarter valued at $41,000. Finally, Almanack Investment Partners LLC. acquired a new stake in AtriCure during the 3rd quarter valued at $43,000. Institutional investors and hedge funds own 99.11% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on ATRC. UBS Group upped their price target on AtriCure from $57.00 to $58.00 and gave the stock a “buy” rating in a research report on Friday, February 16th. Needham & Company LLC upped their price target on AtriCure from $44.00 to $46.00 and gave the stock a “buy” rating in a research report on Friday, February 16th. StockNews.com downgraded AtriCure from a “hold” rating to a “sell” rating in a research report on Wednesday, March 27th. Finally, Stifel Nicolaus reduced their price target on AtriCure from $50.00 to $42.00 and set a “buy” rating for the company in a research report on Friday, February 16th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $55.57.

View Our Latest Analysis on ATRC

About AtriCure

(Get Free Report)

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.

See Also

Insider Buying and Selling by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.